Ondansetrom Tolife (Ondansetron)

Ondansetron is employed across several therapeutic areas to control nausea and vomiting.

• Chemotherapy‑induced nausea and vomiting (CINV): helps reduce the frequency and severity of nausea and vomiting associated with cancer chemotherapy.
• Radiation‑induced nausea and vomiting (RINV): provides relief from nausea and vomiting that occur during or after radiation treatment.
• Post‑operative nausea and vomiting (PONV): reduces the incidence of nausea and vomiting following surgical procedures.

• Ondansetron selectively blocks serotonin (5‑HT3) receptors located on vagal nerve terminals in the gastrointestinal tract and in the chemoreceptor trigger zone of the brain. By inhibiting these receptors, it prevents the initiation of the vomiting reflex triggered by chemical stimuli, thereby reducing nausea and vomiting.

Side effects reported with ondansetron are generally mild to moderate and vary in frequency.

Common Side Effects

• Headache: mild to moderate intensity.
• Constipation: reduced bowel movements.
• Diarrhoea: loose stools.
• Fatigue: feeling of tiredness.
• Dizziness: light‑headed sensation.

Serious or Rare Side Effects

• QT interval prolongation: cardiac rhythm changes that may lead to arrhythmia.
• Severe allergic reaction: rash, itching, swelling, or difficulty breathing.
• Serotonin syndrome: agitation, hyperreflexia, rapid heart rate, and high temperature when combined with other serotonergic agents.
• Hepatic dysfunction: elevated liver enzymes indicating liver stress.
• Vision changes: blurred vision or transient visual disturbances.

When using ondansetron, certain precautions should be observed to ensure safe and effective therapy.

• Cardiac monitoring: patients with known prolonged QT interval or electrolyte abnormalities should be monitored.
• Electrolyte balance: correct potassium, magnesium, and calcium levels before initiating therapy.
• Pregnancy: use only if the potential benefit justifies the potential risk to the fetus.
• Breastfeeding: weigh the benefits against possible infant exposure through milk.
• Drug interactions: review concomitant medications for potential serotonergic or QT‑prolonging effects.
• Store at below 25°C: keep in the original packaging, protect from moisture and direct sunlight.

Ondansetron may interact with several medicines, altering its efficacy or safety profile.

Major Interactions (Avoid)

• Apomorphine: concurrent use can cause profound hypotension and loss of consciousness.
• Certain anti‑arrhythmic drugs (e.g., amiodarone, quinidine): may increase the risk of QT prolongation.

Moderate Interactions (Monitor Closely)

• Other serotonergic agents (e.g., SSRIs, SNRIs, triptans): may raise the risk of serotonin syndrome.
• CYP3A4 inhibitors (e.g., ketoconazole, erythromycin): can increase ondansetron plasma levels.
• CYP2D6 inhibitors (strong) (e.g., fluoxetine, paroxetine): may raise plasma concentrations.
• Diuretics that cause electrolyte loss: may exacerbate QT‑related risks.